RT Journal Article
T1 Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin
A1 Valverde-Fraga, Lorena
A1 Haddad, Razan
A1 Alrabadi, Nasr
A1 Sánchez Poza, María Sandra
A1 Remuñán López, Carmen
A1 Csaba, Noemi Stefania
K1 Chitosan nanocapsules
K1 Rifabutin
K1 PEG-stearate
K1 Lecithin
K1 Antituberculosis treatment
AB Tuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in high doses and for long periods of time. These therapeutic regimens are associated with many side effects and high rates of drug resistance. To overcome these problems, this study aims at developing a nanosystem for the improved delivery of antibiotics, with potential application in pulmonary delivery.Chitosan-based nanomaterials are widely used in biomedical applications, due to their biodegradability and biocompatibility, as well as their potential antimicrobial effects and lack of toxicity. In addition, this polymer is particularly attractive for mucosal delivery due to its bioadhesive properties. Therefore, the structure of the proposed nanocarrier consists of a chitosan shell and a lipid core with a combination of different oils and surfactants to allow optimal association of the hydrophobic drug rifabutin. These nanocapsules were characterized in terms of size, polydispersity index, surface charge, morphology, encapsulation efficiency and biological stability. The release kinetics of the drug-loaded nanostructures was evaluated in simulated lung media. Moreover, in vitro studies in different cell models (A549 and Raw 264.7 cells) demonstrated the safety of the nanocapsules as well as their efficient internalization. An antimicrobial susceptibility test was performed to evaluate the efficacy of the rifabutin-loaded nanocapsules against Mycobacterium phlei. This study indicated complete inhibition for antibiotic concentrations within the expected susceptibility range of Mycobacterium (≤ 0.25–16 mg/L)
PB Elsevier
SN 0928-0987
YR 2023
FD 2023-05-31
LK http://hdl.handle.net/10347/31219
UL http://hdl.handle.net/10347/31219
LA eng
NO European Journal of Pharmaceutical Sciences 187 (2023) 106484
NO This work has received financial support from the Xunta de Galicia (Centro singular de investigación de Galicia, accreditation 2019–2022); Competitive Reference Groups, ED431C 2021/17-FEDER) and Ministerio de Ciencia e Innovación, Gobierno de España (PID2019-107500RB-I00)
DS Minerva
RD 30 abr 2026